BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant
BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of $0.80 per ADS and accompanying warrant. Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx. The warrants will have an exercise price of $0.80 per ADS, will be exercisable at any time upon issuance and will expire five years from the date of issuance. The offering is expected to close on or about April 1, 2024, subject to the satisfaction of customary closing conditions.
BioLinerX Ltd.（纳斯达克股票代码：BLRX）（TASE：BLRX）（“BioLinerX” 或 “公司”）是一家致力于改变生命的肿瘤和罕见疾病疗法的商业阶段生物制药公司，今天宣布，它已与几家机构投资者签订了最终协议，以注册直接发行的形式发行和出售该公司750万股美国存托股份（ADS）和认股权证持有人总共购买最多7,500,000份美国存托凭证，每份ADS和附带的认股权证的总购买价格为0.80美元。每股ADS代表BioLinerX的十五（15）股普通股，面值为每股0.10新谢克尔。认股权证的行使价为每份ADS0.80美元，可在发行后随时行使，并将自发行之日起五年内到期。此次发行预计将于2024年4月1日左右结束，但须满足惯例成交条件。
The gross proceeds from the offering (without taking into account any proceeds from any future exercises of warrants), before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be $6.0 million. BioLineRx intends to use the net proceeds from the offering to support the commercialization of APHEXDA (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in patients with multiple myeloma, advance its pancreatic cancer clinical development program and other pipeline programs, and for general corporate purposes.
在扣除配售代理费和公司应付的其他发行费用之前，此次发行的总收益（不考虑未来行使认股权证的任何收益）预计为600万美元。BioLinerX打算将此次发行的净收益用于支持APHEXDA（motixafortide）的商业化，其在美国的适应症是用于多发性骨髓瘤患者自体移植的干细胞动员，推进其胰腺癌临床开发计划和其他管道项目，以及用于一般公司用途。
"We believe that today's equity transaction, when combined with the potential drawdown of an additional $20 million tranche from our existing debt facility at favorable interest rates, together with our existing cash, provides the Company with the financial resources to continue building our momentum with the APHEXDA launch and advancing key life cycle programs for long-term growth opportunities", said Philip Serlin, Chief Executive Officer of BioLineRx.
BioLinerX首席执行官菲利普·塞林表示：“我们认为，今天的股权交易，加上可能以优惠利率从现有债务融资中再提取2000万美元，再加上我们现有的现金，为公司提供了财政资源，使APHEXDA的启动和推进关键生命周期计划以获得长期增长机会。”
JonesTrading Institutional Services LLC is acting as the exclusive placement agent for the offering.
JoneStrading机构服务有限责任公司是本次发行的独家配售代理。